Patents by Inventor TIMOTHY BOYD
TIMOTHY BOYD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896647Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: GrantFiled: July 24, 2020Date of Patent: February 13, 2024Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Huntington Potter, Gary W. Arendash, Steven Bennett, Timothy Boyd
-
Publication number: 20240041980Abstract: Embodiments of the instant disclosure relate to novel methods for treatment of one or more pathologic entities of Type 2 diabetes. In certain embodiments, methods concern reducing the risk of developing, preventing and/or treating a pathologic entity of Type 2 diabetes or other condition having a pathologic entity component by administering to a subject in need thereof a granulocyte macrophage colony stimulating factor (GM-CSF) or recombinantly produced molecule or fragment thereof, or an analog thereof. In other embodiments, methods concern decreasing pancreatic islet amyloid deposition in a subject by administering to the subject, GM-CSF or recombinantly produced molecule or fragment thereof, or an analog thereof, wherein the subject has pancreatic islet amyloid deposition.Type: ApplicationFiled: August 25, 2023Publication date: February 8, 2024Inventors: Huntington POTTER, Timothy BOYD, Ching-Jung WANG
-
Publication number: 20230364191Abstract: Embodiments of the instant disclosure relate to novel methods for treatment of a neurodegenerative disease or condition. In certain embodiments, methods of alleviating a neurodegenerative disease in a subject include administering an effective concentration of granulocyte macrophage colony stimulating factor (GM-CSF); monitoring an absolute number of at least one of leukocytes, concentration of at least one inflammatory cytokine, concentration of at least one neurodegenerative condition biomarker, or a combination thereof in the subject; and adjusting GM-CSF treatment regimens based the level of at least one of these parameters. In some embodiments, methods of alleviating a neurodegenerative condition in a subject can further include performing at least one cognition assessment test before and after GM-CSF treatment and adjusting the GM-CSF treatment regimen based on observations in the cognitive state of the subject before and after administration of GM-CSF.Type: ApplicationFiled: July 27, 2023Publication date: November 16, 2023Inventors: Huntington Potter, Timothy Boyd, Stefan Sillau
-
Publication number: 20230085071Abstract: Embodiments herein relate to novel compositions and methods for treating viral infections and viral infection-related conditions. In some embodiments, compositions include, but are not limited to, at least one pro-inflammatory cytokine. In accordance with these embodiments, a proinflammatory cytokine can include Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) alone or in combination with other agents administered separately or together. In some embodiments, compositions including GM-CSF can be administered to a subject exposed to, suspected of having been exposed to, or having a viral infection. In other embodiments, the compositions treat, ameliorate or prevent a complication related to viral infection including, but not limited to, a central nervous system infection or condition and a lung infection or condition.Type: ApplicationFiled: September 16, 2022Publication date: March 16, 2023Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Huntington Potter, Timothy Boyd, Penny Clarke, Kenneth L. Tyler, Lon Kendall, Sarah Stonedahl
-
Publication number: 20210348242Abstract: The present disclosure relates generally to methods for measuring the titer and potency of viral vector particles, including methods which use qPCR, ddPCR, or a combination thereof to measure the titer of the viral vector particles.Type: ApplicationFiled: October 4, 2019Publication date: November 11, 2021Inventors: Lauren M. Drouin, Carlo Ciatto, Patrick Starremans, Joseph Mombeleur, Rachael Ahern, Timothy Boyd, Eric D. Horowitz
-
Publication number: 20210106654Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fins-related tyrosine kinase 3 (Fltt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1 alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: July 24, 2020Publication date: April 15, 2021Applicant: University of South FloridaInventors: HUNTINGTON POTTER, GARY W. ARENDASH, STEVEN BENNETT, TIMOTHY BOYD
-
Patent number: 10806772Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: GrantFiled: July 10, 2017Date of Patent: October 20, 2020Assignees: UNIVERSITY OF SOUTH FLORIDA, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Huntington Potter, Timothy Boyd, Heather Sevey Lawrence Jim
-
Publication number: 20200171128Abstract: The present invention provides a method of improving cognition, stabilizing cognition, and/or reversing loss of cognition in a subject in need thereof. In certain embodiments, the subject is administered a therapeutically effective account of GM-CSF or any biologically active derivative or analogue thereof.Type: ApplicationFiled: May 18, 2018Publication date: June 4, 2020Inventors: Huntington Potter, Timothy Boyd, Ching-Jung Wang, Md. Mahiuddin Ahmed
-
Publication number: 20170368142Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: July 10, 2017Publication date: December 28, 2017Inventors: HUNTINGTON POTTER, TIMOTHY BOYD, HEATHER SEVEY LAWRENCE JIM
-
Patent number: 9700597Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: GrantFiled: June 4, 2015Date of Patent: July 11, 2017Assignees: UNIVERSITY OF SOUTH FLORIDA, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Huntington Potter, Timothy Boyd, Heather Sevey Lawrence Jim
-
Publication number: 20170189490Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: March 15, 2017Publication date: July 6, 2017Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: HUNTINGTON POTTER, GARY W. ARENDASH, STEVEN BENNETT, TIMOTHY BOYD
-
Patent number: 9682124Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: GrantFiled: December 31, 2013Date of Patent: June 20, 2017Assignee: University of South FloridaInventors: Huntington Potter, Gary W. Arendash, Steven Bennett, Timothy Boyd
-
Publication number: 20150265678Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: June 4, 2015Publication date: September 24, 2015Inventors: HUNTINGTON POTTER, TIMOTHY BOYD, HEATHER SEVEY LAWRENCE JIM
-
Patent number: 9132168Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: GrantFiled: June 21, 2011Date of Patent: September 15, 2015Assignees: UNIVERSITY OF SOUTH FLORIDA, H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Huntington Potter, Timothy Boyd, Heather Sevey Lawrence Jim
-
Patent number: 9050738Abstract: A method and apparatus for cutting rigid, brittle articles such as tile used as a building material is improved by the capability to make both straight and curved cuts in tile on a single machine. The machine has both circular and plunge cutting tools and a table for moving the tile in both curved and straight lines in relation to the cutting tool, thereby achieving both curved and straight cuts.Type: GrantFiled: February 4, 2014Date of Patent: June 9, 2015Inventors: Adam Timothy Boyd, Benjamin Frank
-
Patent number: 8870006Abstract: Provided is a hot-fill container adapted to provide vertical vacuum compensation in response to negative pressure inside the container. The container comprises one or more horizontal ribs that are configured to diminish in height in response to vacuum conditions inside the container. Each rib comprises an upper wall connected to a lower wall. The upper and lower walls are inclined from a horizontal reference line and adapted to hinge with respect to each other to provide vertical vacuum compensation.Type: GrantFiled: April 30, 2009Date of Patent: October 28, 2014Assignee: Plastipak Packaging, Inc.Inventors: Satya Kamineni, Michael R. Mooney, Timothy Boyd
-
Publication number: 20140255337Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: December 31, 2013Publication date: September 11, 2014Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: HUNTINGTON POTTER, GARY W. ARENDASH, STEVEN BENNETT, TIMOTHY BOYD
-
Publication number: 20140144419Abstract: A method and apparatus for cutting rigid, brittle articles such as tile used as a building material is improved by the capability to make both straight and curved cuts in tile on a single machine. The machine has both circular and plunge cutting tools and a table for moving the tile in both curved and straight lines in relation to the cutting tool, thereby achieving both curved and straight cuts.Type: ApplicationFiled: February 4, 2014Publication date: May 29, 2014Inventors: Adam Timothy Boyd, Benjamin Frank
-
Publication number: 20120061410Abstract: Provided is a hot-fill container adapted to provide vertical vacuum compensation in response to negative pressure inside the container. The container comprises one or more horizontal ribs that are configured to diminish in height in response to vacuum conditions inside the container. Each rib comprises an upper wall connected to a lower wall. The upper and lower walls are inclined from a horizontal reference line and adapted to hinge with respect to each other to provide vertical vacuum compensation.Type: ApplicationFiled: April 30, 2009Publication date: March 15, 2012Applicant: Constar International ,Inc.Inventors: Satya Kamineni, Michael R. Mooney, Timothy Boyd
-
Publication number: 20110311473Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.Type: ApplicationFiled: June 21, 2011Publication date: December 22, 2011Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: HUNTINGTON POTTER, Gary W. Arendash, Steven Bennett, Timothy Boyd